New Technology Partnering & Licensing Panel at ARDD2026

Value of the Information & Strength of the Argument

The discussion provides valuable insights into the strategic considerations of pharma and investors regarding aging research. Panelists argue from their direct experience, with concrete examples such as GSK’s collaboration with Relation Therapeutics and Genentech’s approach to data sharing. Carl Gordon’s frank analysis of why few deals target aging directly (near-term revenue needs) is particularly enlightening. The argumentation is coherent, with each expert contributing unique perspectives, though some divergence exists on the definition of aging research. Overall, the panel offers a nuanced view of the barriers and opportunities in this nascent field.

Scientific Rigor, Source Quality, Title Accuracy

The panelists cite specific market data from J.P. Morgan, Deal Pharma, BioBucks, and a LongevityTechnology report, enhancing credibility. However, no peer-reviewed scientific sources are referenced; the focus is on business and regulatory aspects. The title is accurate and well-matched to the content, which revolves around partnering and licensing in new technology contexts. The discussion demonstrates strong integration of current market trends with expert opinions, though it lacks direct citation of primary literature.

The title accurately reflects the panel's focus on new technology partnering and licensing in aging research.

8/10

Panelists are senior executives from major pharmaceutical companies and investment firms (GSK, Genentech, Astellas, OrbiMed), providing credible insights. Market data and deal examples are referenced, enhancing reliability.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction and market data on licensing deals growth (166.7 billion in H1 2026).
• 08:00Definition of aging research: panelists share perspectives on how it differs from disease-specific research.
• 16:00Christopher Austin discusses unified mechanisms underlying aging and GSK's focus on immune aging.
• 24:00Discussion on FDA regulatory science and its potential impact on future P&L deals.
• 34:00Trends in partnering: holistic platforms, pre-competitive data sharing, and AI collaboration strategies.
• 45:00Carl Gordon explains why few aging-specific deals occur, citing revenue pressures and near-term needs.

• ARDD Official Website — Conference website for ARDD, the event where this panel took place.
• ARDD LinkedIn — LinkedIn page for updates on ARDD and related content.